Literature DB >> 31785234

Evaluation of a Multiplex Strip PCR Test for Infectious Uveitis: A Prospective Multicenter Study.

Satoko Nakano1, Yasuhiro Tomaru2, Toshiaki Kubota1, Hiroshi Takase3, Manabu Mochizuki4, Norio Shimizu2, Sunao Sugita5.   

Abstract

PURPOSE: A novel multiplex polymerase chain reaction (PCR) test (Strip PCR) for 24 common ocular infectious disease pathogens was established. Solid-phase techniques provide stable, prompt, and accurate results while using less sample amount with lower cost than conventional quantitative real-time PCR (qPCR). Strip PCR for infectious uveitis was optimized and evaluated using intraocular samples.
DESIGN: Evaluation of diagnostic testing.
METHODS: We examined 722 samples at 14 institutions. Genomic DNA from aqueous humor and vitreous fluid was analyzed by qPCR and Strip PCR. Clinical diagnosis was determined based on symptoms, clinical findings, and laboratory tests. MainOutcomeMeasures: The diagnostic parameters of the Strip PCR were based on qPCR results.
RESULTS: Strip PCR showed low intra- and inter-institutional variability even when performed by technicians with various PCR skill levels. The targets of Strip PCR for infectious uveitis were optimized for 9 major pathogens (herpes simplex virus [HSV] 1, HSV2, varicella-zoster virus, human T-cell lymphotropic virus 1, human herpesvirus 6, Epstein-Barr virus, cytomegalovirus, Toxoplasma gondii, and Treponema pallidum) with 772 intraocular samples. The Strip PCR successfully detected pathogen DNA at concentrations ranging from 100 to 109 copies/mL in 252 of the 255 qPCR-positive samples. It yielded negative results for all the 191 qPCR-negative samples. Strip PCR had higher sensitivity (98.8%), specificity (98.5%), positive predictive value (98.8%), and negative predictive value (98.5%) than qPCR, with distinct primers. The Strip PCR results had strong correlation with that of the qPCR (r = 0.838) and they were consistent with the clinical diagnosis.
CONCLUSIONS: Easy-to-use Strip PCR is recommended for rapid diagnosis of infectious uveitis, as its results are equivalent to that of conventional qPCR.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31785234     DOI: 10.1016/j.ajo.2019.10.031

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

Review 1.  Vitreoretinal surgery in the management of infectious and non-infectious uveitis - a narrative review.

Authors:  Jia-Horung Hung; Narsing A Rao; Wei-Chun Chiu; Shwu-Jiuan Sheu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-10-12       Impact factor: 3.535

2.  Safety and efficacy of 27-gauge transconjunctival vitrectomy for the diagnosis of posterior uveitis or pan uveitis of unknown origin.

Authors:  Atsushi Sakai; Mizuki Tagami; Norihiko Misawa; Manabu Yamamoto; Takeya Kohno; Shigeru Honda
Journal:  BMC Ophthalmol       Date:  2022-04-19       Impact factor: 2.086

3.  Uveo-meningeal syndrome secondary to Herpes Simplex Virus related acute retinal necrosis.

Authors:  Megan Haghnegahdar; Dante Pennipede; Brenton Massey; Mary Champion; Radwan Ajlan
Journal:  Am J Ophthalmol Case Rep       Date:  2022-02-09

4.  A Case of Frosted Branch Angiitis in the Age of Polymerase Chain Reaction: Diagnostic and Therapeutic Considerations.

Authors:  Moises Enghelberg; David I Sierpina
Journal:  Cureus       Date:  2022-09-05

5.  Effective diagnosis by real-time PCR of herpes simplex diffuse endotheliitis that is similar in appearance to fungal keratitis: case series.

Authors:  Daisuke Todokoro; Mayumi Hosogai; Satoko Nakano; Hideo Akiyama
Journal:  J Ophthalmic Inflamm Infect       Date:  2021-07-12

6.  Long-term outcome in corneal endotheliitis with molecular detection of herpes simplex virus 1 and human herpes virus 6: a case report.

Authors:  Takashi Ono; Takuya Iwasaki; Yukiko Terada; Yosai Mori; Ryohei Nejima; Mineo Ozaki; Manabu Mochizuki; Kazunori Miyata
Journal:  BMC Ophthalmol       Date:  2022-02-02       Impact factor: 2.209

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.